Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC

Inclusion Criteria: * Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent * Female subjects 18 years of age or older * Histologically confirmed cT1c-T3N0, cT1-T3N1-N2, cTxN1-2 TNBC * The invasive tumor must be hormone receptor poor, defined as both estrogen receptor (ER) and progesterone receptor staining in ≤ 10% of invasive cancer cells by IHC * The invasive tumor must be HER2-negative based on the current ASCO-CAP guidelines * No previous ipsilateral breast surgery for the current breast cancer * No previous chemotherapy, immunotherapy, endocrine therapy, or radiotherapy for the current breast cancer * ECOG Performance Status 0 - 1 documented within 21 days prior to the start of study treatment * Breast and axillary imaging (including ultrasound and MRI) within 42 days (6 weeks) prior to treatment initiation * Subjects with clinically and/or radiographically abnormal axillary or internal mammary lymph nodes should have pathologic confirmation of disease status with image-guided biopsy or fine needle aspiration * Archival breast tumor tissue has been obtained or has been requested for use * No clinically apparent metastatic disease. Staging to rule out metastatic disease is suggested for patients with clinical TNM stage III disease * Subjects with bilateral synchronous TNBC are eligible if they meet other eligibility criteria * No baseline neuropathy greater t…